{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:32:51Z","timestamp":1793658771067,"version":"4.5.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFE0213800"],"award-info":[{"award-number":["2024YFE0213800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015800","name":"Jilin Province Development and Reform Commission","doi-asserted-by":"publisher","award":["2023C015"],"award-info":[{"award-number":["2023C015"]}],"id":[{"id":"10.13039\/100015800","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202401328ZYTS"],"award-info":[{"award-number":["YDZJ202401328ZYTS"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52203168"],"award-info":[{"award-number":["52203168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20365"],"award-info":[{"award-number":["U24A20365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271319"],"award-info":[{"award-number":["32271319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002838","name":"Changchun Institute of Applied Chemistry, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2024-JCXK-11"],"award-info":[{"award-number":["2024-JCXK-11"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023-JCXK-25"],"award-info":[{"award-number":["2023-JCXK-25"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113832","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:00:03Z","timestamp":1746777603000},"page":"113832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Reversing the immunosuppressive tumor microenvironment via \u201cKynurenine starvation therapy\u201d for postsurgical triple-negative breast cancer treatment"],"prefix":"10.1016","volume":"383","author":[{"given":"Zengguang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengcai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanshun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113832_bb0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113832_bb0010","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"30","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2025.113832_bb0015","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113832_bb0020","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive Cancer network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.113832_bb0025","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.113832_bb0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0035","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","article-title":"Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers","volume":"10","author":"Song","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.113832_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113832_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.113832_bb0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2025.113832_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41416-023-02245-7","article-title":"Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials","volume":"129","author":"Girithar","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113832_bb0065","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nbt.4180","article-title":"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0070","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1038\/s41467-022-31579-8","article-title":"An in situ hydrogel-mediated chemo-immunometabolic cancer therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113832_bb0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113832_bb0085","doi-asserted-by":"crossref","first-page":"20768","DOI":"10.1073\/pnas.1009201107","article-title":"An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis","volume":"107","author":"Quintana","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113832_bb0090","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113832_bb0095","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.113832_bb0105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2025.113832_bb0110","doi-asserted-by":"crossref","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Naour","year":"2020","journal-title":"Oncoimmunol"},{"key":"10.1016\/j.jconrel.2025.113832_bb0115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0120","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","article-title":"Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment","volume":"10","author":"G\u00fcnther","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113832_bb0130","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1021\/acsami.4c00513","article-title":"Metabolic modulation of kynurenine based on kynureninase-loaded nanoparticle depot overcomes tumor immune evasion in cancer immunotherapy","volume":"16","author":"Chae","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.113832_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007247","article-title":"Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy","volume":"33","author":"Zeng","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113832_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108055","article-title":"Recent advances in clinical trials targeting the kynurenine pathway","volume":"236","author":"Pires","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.113832_bb0145","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20221682","article-title":"Tryptophan metabolism and disposition in cancer biology and immunotherapy","volume":"42","author":"Badawy","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2025.113832_bb0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jconrel.2024.06.067","article-title":"Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy","volume":"372","author":"Ma","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113832_bb0155","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1038\/s41467-019-11730-8","article-title":"Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence","volume":"10","author":"Song","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113832_bb0160","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.apsb.2021.09.021","article-title":"Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy","volume":"12","author":"Ye","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.113832_bb0165","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.biomaterials.2010.09.053","article-title":"Delivery of rosiglitazone from an injectable triple interpenetrating network hydrogel composed of naturally derived materials","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113832_bb0170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jconrel.2022.11.028","article-title":"Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy","volume":"353","author":"Si","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113832_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1015866104055","article-title":"Determination of degree of substitution of formyl groups in polyaldehyde dextran by the hydroxylamine hydrochloride method","volume":"8","author":"Zhao","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113832_bb0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2021.11.027","article-title":"A spatiotemporal release platform based on pH\/ROS stimuli-responsive hydrogel in wound repairing","volume":"341","author":"Wu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113832_bb0185","doi-asserted-by":"crossref","first-page":"1801664","DOI":"10.1002\/advs.201801664","article-title":"Self-healing hydrogels: the next paradigm shift in tissue engineering?","volume":"6","author":"Talebian","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113832_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumor","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.113832_bb0195","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1039\/C7MT00105C","article-title":"Heme-containing enzymes and inhibitors for tryptophan metabolism","volume":"9","author":"Yan","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.jconrel.2025.113832_bb0200","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.9b01079","article-title":"N-benzyl\/aryl substituted tryptanthrin as dual inhibitors of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.113832_bb0205","doi-asserted-by":"crossref","DOI":"10.1039\/D3CP06036E","article-title":"A theoretical study on the activity and selectivity of IDO\/TDO inhibitors","volume":"26","author":"Wujieti","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jconrel.2025.113832_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120190","article-title":"Oxaliplatin-\/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer","volume":"255","author":"Shen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113832_bb0215","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1172\/JCI131859","article-title":"Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells","volume":"130","author":"Oh","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.113832_bb0220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jconrel.2023.02.042","article-title":"Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel","volume":"356","author":"Mi","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113832_bb0225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41467-025-55904-z","article-title":"Injectable supramolecular hydrogel co-loading abemaciclib\/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113832_bb0230","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","article-title":"Breast cancer lung metastasis: molecular biology and therapeutic implications","volume":"19","author":"Jin","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2025.113832_bb0235","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113832_bb0240","article-title":"Selectively potentiating hypoxia levels by Combretastatin A4 nanomedicine: toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors","volume":"31","author":"Yang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113832_bb0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.113832_bb0250","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.113832_bb0255","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41423-021-00726-4","article-title":"Dendritic cell migration in inflammation and immunity","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0260","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113832_bb0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:11:59Z","timestamp":1752570719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":53,"alternative-id":["S0168365925004523"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113832","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversing the immunosuppressive tumor microenvironment via \u201cKynurenine starvation therapy\u201d for postsurgical triple-negative breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113832"}}